Empirical therapy advisor

Before culture results are back: how likely is each antibiotic to cover the pathogen of a patient like this one, in this ward, given the last 12 months of results and today's alerts.

Patient

More options · any onset · target 80 % · 2026-02-15
Based on 373 first isolates · MED-B · Cystitis (lower UTI) · 2025-02-16 → 2026-02-15
Internal medicine B
Per-organism detail: MED-B urine resistance view →
Narrowest option reaching 80 % coverage, no active warning
nitrofurantoin 83 % (79 %–87 %)
No tissue or blood levels: cystitis only.
Not covered: Proteus mirabilis (8 %), Klebsiella pneumoniae (5 %), Pseudomonas aeruginosa (3 %)
AntibioticCoverage, 12 months (95 % CI)12 mo4 wk
meropenem MEM
trend · Escherichia coli reserve
88 %
90 %
n = 21
nitrofurantoin NIT
trend · Escherichia coli lower UTI only
83 %
71 %
n = 21
piperacillin-tazobactam TZP
trend · Escherichia coli broad spectrum
83 %
81 %
n = 21
ciprofloxacin CIP
trend · Escherichia coli
82 %
90 %
n = 21
mecillinam MEC
trend · Escherichia coli lower UTI only
80 %
76 %
n = 21
ceftriaxone CRO
trend · Escherichia coli
80 %
71 %
n = 21
77 %
71 %
n = 21
trimethoprim TMP
trend · Escherichia coli lower UTI only
72 %
71 %
n = 21
46 %
38 %
n = 21
vancomycin VAN
trend · Enterococcus faecalis Gram-positive only
10 %
5 %
n = 21
3 %
10 %
n = 21
clindamycin CLI
trend · Staphylococcus aureus Gram-positive only
3 %
0 %
n = 21

Most likely organisms for this profile

Escherichia coli
58 %
Klebsiella pneumoniae
12 %
Proteus mirabilis
8 %
Enterococcus faecalis
8 %
Citrobacter freundii
4 %
Pseudomonas aeruginosa
3 %

Decision support only: coverage is the share of first isolates from similar patients that were susceptible (an organism not tested for a drug counts as not covered). It does not replace local treatment guidelines, allergy and severity assessment, or clinical judgement. The black tick on each bar is the coverage target; the bracket is the 95 % confidence interval.

AEI · Tyks Laboratoriot × Mylab · JunctionX Turku. Synteettinen aineisto; EARS-Net-luvut: ECDC.